EODM DTO 1440/4 1 D (1:5-1 DTO/CD/09)	APPLICATION NO.:	10/644,052	ATTY. DOCKET NO.: C1037.70048US00		
FORM PTO-1449/A and B (modified PTO/SB/08)	FILING DATE:	August 19, 2003	CONFIRMATION NO.: 4791		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT:	Krieg et al.			
Sheet b of 2	GROUP ART UNIT:	1645	EXAMINER:	Nina Archie	

A STATE OF THE STA	U.S. Patent Doo		PATENT DOCUMENTS	Date of Publication or Issue	
Examiner's ADB 1 No.	Number Kind Code		Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	
	6,348,312	B1	Peyman et al.	02-19-2002	
	6,589,940	B1	Raz et al.	07-08-2003	
	6,943,240	B2	Bauer et al.	09-13-2005	
	7,176,296	B2	Agrawal et al.	02-13-2007	
	7,255,868	B2	Fearon et al.	08-14-2007	
	7,271,156	B2	Krieg et al.	07-18-2007	
	2003-0129605	A1	Yu et al.	07-10-2003	
	2005-0009773	A1	Kandimalla et al.	01-13-2005	
	2005-0244380	A1	Krieg et al.	11-03-2005	
	2005-0245477	A1	Krieg et al.	11-03-2005	
	2006-0019918	A1	Agrawal et al.	01-26-2006	
	2007-0184465	A1	Wagner et al.	08-09-2007	
	2007-0202128	A1	Krieg et al.	08-30-2007	
	2007-0224210	A1	Krieg et al.	09-27-2007	
	2007-0232622	A1	Lipford et al.	10-04-2007	
	2008-0009455	A9	Krieg et al.	01-10-2008	
	2008-0026011	A1	Krieg et al.	01-31-2008	
	2008-0031936	A1	Krieg et al.	02-07-2008	
	2008-0045473	A1	Uhlmann et al.	02-21-2008	

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite	Foreign Patent Document		nent	Name of Patentee or Applicant of Cited	Date of Publication of	Translation
	No.	Office/ Country	Number	Kind Code	Document Document	Cited Document MM-DD-YYYY	(Y/N)
		wo	98/16247	A1	The Regents of the University of California	04-23-1998	
		wo	98/18810	A1	University of Iowa Research Foundation	05-07-1998	
		wo	00/14217	A2	CPG Immunopharmaceuticals GMBH	03-16-2000	
		wo	00/67023	A1	CPG Immunopharmaceuticals GMBH	11-09-2000	
		wo	01/22972	A2	Coley Pharmaceuticals, GmbH	04-05-2001	
		wo	01/22990	A2	Coley Pharmaceutical Group, Inc.	04-05-2001	
		wo	03/015711	A2	Coley Pharmaceutical Group, Inc.	02-27-2003	
		WO	03/035836	A2	Hybridon, Inc.	05-01-2003	

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

					10/644.052	ATTY DOG	VET NO. C1027	002118000
FORM PTO-1449/A and B (modified PTO/SB/08)			APPLICATION NO.: 10/644,052		ATTY. DOC	ATTY. DOCKET NO.: C1037.70048US00		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: August 19, 2003		CONFIRMA	CONFIRMATION NO.: 4791			
		APPLICA	APPLICANT: Krieg et al.					
Cl		of 2		GROUP ART UNIT: 1645 EXAMI		EXAMINER	NER: Nina Archie	
Sheet	2	of	2	<u> </u>				
·		wo	2004/007743	A2	Coley Pharmaceutical GMF	BH	01-22-2004	
		wo	2004/026888	A2	Coley Pharmaceutical GMI		04-01-2004	
		wo	2004/039829	A2	Coley Pharmaceutical Grou		05-13-2004	
		wo	2004/053104	A2	Coley Pharmaceutical Grou		06-24-2004	
		wo	2004/087203	A2	Coley Pharmaceutical Grou		10-14-2004	
		wo	2004/094671	A2	Coley Pharmaceutical GMI		11-04-2004	
	 	wo	2006/080946	A2	Coley Pharmaceutical GMBH		08-03-2006	
		wo	2007/031877	A2	Coley Pharmaceutical GMI		03-22-2007	
	 	wo	2007/031877	A2	Coley Pharmaceutical GMI		04-05-2007	
	L	WO		·	· · · · · · · · · · · · · · · · · · ·			 .
			OTHER A	RT — NON	PATENT LITERATURE DO	CUMENTS	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
Examiner's Initials #	Cite No	Include (book, m	name of the author agazine, journal, so	erial, sympo	AL LETTERS), title of the articlesium, catalog, etc.), date, page(sy and/or country where published)	cle (when appropriate), title of the item (s), volume-issue number(s), publisher, ed. Translatio (Y/N)		
		GOLDBI	ERG et al., Beyon	nd danger:	unmethylated CpG dinucleot	ides and the imn	nunopathogenesis	
		of disease	e. Immunol Lett.	2000 Jul 3	3;73(1):13-8.			
HARTMANN et al., Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol. 2003						3 cell activation 03		
	Jun;33(6):1633-41.							
		KANDIN	MALLA et al., Se	condary s	tructures in CpG oligonucleot	ides affect immu	inostimulatory	ł
					mun. 2003 Jul 11;306(4):948			
	 	KRIEG,	Now I know my	CpGs. Frei	nds Microbiol. 2001 Jun;9(6) oligonucleotide sequences wi	th high induction	of IFN-	
		alpha/het	t al., Identification	ni oi CpG d dendritic	cells. Eur J Immunol. 2001	ul:31(7):2154-63	3.	
	 	MUTWI	RI et al., Biologi	cal activity	of immunostimulatory CpG	DNA motifs in c	lomestic animals.	
		Vet Imm	unol Immunopat	hol. 2003.	Jan 30;91(2):89-103.			
	VOLLMER, CpG motifs to modulate innate and adaptive immune responses. Int Rev Immunol. 2006 May-Aug;25(3-4):125-34.						Rev Immunol.	
a copy of this re	eference is r	not provided a	<u>, </u>	ted by or sub	mitted to the office in a prior applica	tion, Serial No,	filed , and relied upor	n for an earlier
NOTE – No copure included. See	oies of U.S. 37 CFR §1 ired by 37 (patents, publi 1.98 and 1287 CFR §1.98 unl	shed U.S. patent appl	lications, or p	ending, unpublished patent applicati (s), publication(s), unpublished, pend in an IDS in an earlier application th	ling U.S. patent appli	ications, or other inform	ation hated are
					DATE CONSIDER	ED.		
EXAMINER	:				DATE CONSIDER	uu.		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.